Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study.

By J. Daemen, P. Wenaweser, K. Tsuchida, Linda Abrecht, S. Vaina, Cyrill Morger, N. Kukreja, Peter Jüni, G. Sianos, G. Hellige and 6 more. The Lancet, 2007

1,769 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/cbfe047ddc02960b2d1e30441db9c390de9cf83e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. W. Wijns
2. F. Feres
3. Philippe Kolh
4. S. King
5. H. Gwon
6. J. Knuuti
7. Nicolas Danchin
8. R. Costa

Citations in the corpus

• Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. (2009, result): “lopidogrel therapy at the time of the ST in the first 6 onths after the index PCI was identified as the strongest ndependent predictor of ST, and this observation is in line ith some (1,2,11) but not all (3,7) previous reports.”
• Guidelines on myocardial revascularization. (2010, background): “Convincing data exist only for continuation up to 6 months [237].”
• Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) Randomized, Multicenter Study (2012, background): “However, some long-term observational studies have reported that the risk of death or myocardial infarction was higher after drug-eluting stents than after bare-metal ones, which may be due to the different incidences of late or very late stent thrombosis.(4,5) Previous observational studies reporte”
• The Pathology of Neoatherosclerosis in Human Coronary Implants: Bare Metal and Drug-Eluting Stents (2011, neutral): “9% at 3 years, involving an all-comer registry of 8,146 patients (22).”